What Is WST Fair Value?
West Pharmaceutical Services (WST) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, West Pharmaceutical Services (WST) has a composite fair value estimate of $115.17 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $359.00, suggesting the stock is overvalued by 67.9%.
Data as of July 16, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$115.17
vs. current price of $359.00(-67.9%)
How Is WST Fair Value Calculated?
Four independent models estimate what WST is worth. Each uses different inputs and assumptions. The composite blends them by weight.
WST Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$136.66
-61.9%Overvalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$27.70
-92.3%Overvalued
Inputs used
WST Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$90.42
-74.8%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$128.55
-64.2%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $359.00 is 61.9% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $425.5M | $384.1M |
| Year 2 | $489.0M | $398.4M |
| Year 3 | $562.0M | $413.3M |
| Year 4 | $645.8M | $428.7M |
| Year 5 | $742.2M | $444.7M |
| Year 6 | $852.9M | $461.3M |
| Year 7 | $980.2M | $478.5M |
| Year 8 | $1.13B | $496.3M |
| Year 9 | $1.29B | $514.8M |
| Year 10 | $1.49B | $534.0M |
| Terminal Value | $18.40B | $6.60B |
What Are WST's Key Financial Metrics?
Earnings & Growth
Current Price
$359.00
EPS (TTM)
$7.50
Forward P/E
37.3
Profit Margin
16.8%
Cash & Balance Sheet
Free Cash Flow
275.7M
EBITDA
869.9M
Book Value
$42.18
Total Debt
321M
What Do Analysts Say About WST?
Low
$310.00
Average
$382.00
High
$447.00
Upside
+6.4%
WST Fair Value FAQ
What is the fair value of WST?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), WST's estimated fair value is $115.17. The stock is currently trading at $359.00, which makes it overvalued by our analysis.
How is WST's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is WST overvalued or undervalued?
Based on our analysis, WST is overvalued. The current price of $359.00 is 67.9% above our estimated fair value of $115.17.
What do Wall Street analysts say about WST?
15 analysts cover West Pharmaceutical Services with a consensus rating of "Strong Buy." The average price target is $382.00, ranging from $310.00 to $447.00. This implies 6.4% upside from the current price.